Biopharma Company Retrotope Files for Bankruptcy in Delaware

Retrotope Inc., a biopharmaceutical company, filed for Chapter 11 bankruptcy in Delaware on Monday.

• Company estimates assets of as much as $1 million and liabilities of as much as $10 million, per court papers
• Retrotope hired SSG Capital Advisors as investment banker and Rock Creek Advisors as financial consultant, bankruptcy petition shows
• The California-based company has “a pipeline of first-in-class therapeutic candidates for the treatment of a range of devastating degenerative diseases,” according to its website
• The case is Retrotope Inc., 22-10228, U.S. Bankruptcy Court for the District of Delaware

To contact the reporter on this story:
Jeremy ...